A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors

A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors David P. Ryan, Thomas Puchalski, Jeffrey G. Supko, David Harmon, Leah Butkiewicz, Robert Maki, Rocio Garcia-Carbonero, Caroline Kuhlman, Jennifer Winkelman, Priscilla Merriam, Travis Quigley, Jose Jimeno, Judith Manola, George D. Demetri Oncologist 2002; 7: 531-538 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gastrointestinal cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the mechanism of action, administration, and pharmacokinetics of ecteinascidin 743. Recognize the classification and pathophysiology of gastrointestinal stromal tumors. Appreciate that conventional cytotoxic chemotherapy has no efficacy in patients with gastrointestinal stromal tumors and that STI571 has dramatic efficacy. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 18, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Dec. 18, 2002 Date Credit Expires: June 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.